Clinical Trials | January 06, 2026
BioInvent’s experimental combo shows promise in hard-to-treat ovarian cancer
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
Elanco expects Befrena to launch in the US in the first half of 2026
Biotium reports that GlycoLiner Labelling is fully covalent and compatible with standard fixation and permeabilization protocols
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The company views ESG reporting as a strategic tool to build trust with clients, investors, regulators, and stakeholders worldwide
Subscribe To Our Newsletter & Stay Updated
